Quetiapine for Visual Hallucinations in Parkinson’s Disease
Dosing Recommendations
Safety and Monitoring
Baseline Assessments
Ongoing Monitoring
Comparative Safety with Other Antipsychotics
Evidence Summary
Management of Hallucinations in Parkinson's Disease with Dementia
Assessment and Medication Optimization
- Visual hallucinations are extremely common in Parkinson's disease with dementia, occurring in up to 80% of patients 3
- The American Academy of Neurology recommends assessing for delirium, which may present similarly to hallucinations but requires different management 4
Medication Optimization Algorithm
- Levodopa/carbidopa is known to worsen psychotic symptoms while improving motor symptoms, and increases in levodopa may help motor symptoms at the cost of worsening psychotic symptoms 3, 5
- Administering levodopa at least 30 minutes before meals can maximize absorption and efficacy, and a protein redistribution dietary regimen can help maximize levodopa efficacy while minimizing side effects 6, 7
- Quetiapine is the preferred atypical antipsychotic for Parkinson's disease psychosis, with a starting dose of 12.5 mg twice daily and a maximum dose of 200 mg twice daily 4
- Avoid typical antipsychotics, such as haloperidol and fluphenazine, as they worsen motor symptoms 4
Addition of Cholinesterase Inhibitor
- Rivastigmine has demonstrated benefit for visual hallucinations in dementia with Lewy bodies, and can improve both cognitive function and neuropsychiatric symptoms without worsening parkinsonian features 3
Monitoring and Follow-up
- Monitor for worsening motor symptoms when adjusting antipsychotics, and provide education and emotional support to families and caregivers 4